Alpine Immune Sciences (ALPN) 10-Q2022 Q1 Quarterly report

Filed: 12 May 22, 4:25pm

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. senior Avg

New words: AACR, absence, adequacy, Alliance, alteration, altered, Assent, assume, Attorney, basket, batch, billion, bioresearch, blizzard, brand, breadth, breakdown, Brexit, bridging, Britain, California, cardiogenic, CCPA, CDPA, central, certainty, choroidal, CJEU, Colorado, Commissioner, conflict, Connecticut, corrective, Correctly, corrupt, CPA, CPOMA, CPRA, CTR, cyber, DAC, davoceticept, death, deliver, deny, deployment, destruction, disaggregated, dissemination, divergent, drop, electrical, encouraging, expend, explicitly, fall, FCPA, February, foreseen, GDPR, geopolitical, GMP, Great, Horizon, identification, improperly, indirect, inflation, inflationary, Inspector, instability, internationally, ipilimumab, jeopardize, jointly, Justice, Korea, labor, landscape, lift, lodge, macroeconomic, malfunction, mark, melanoma, memory, mission, mutual, narrow, narrowing, necessity, NEON, nivolumab, Northern, Online, opt, opted, pace, partnership, perspective, phishing, Poland, portal, pre, predecessor, predominantly, pretreated, prompted, publicly, pursuit, reimpose, relegated, reliability, repealing, replicated, reproduce, rescinding, resource, retention, revocation, revoke, revoked, Royal, Russia, satisfactorily, sequester, Shield, shock, sociopolitical, staffing, strategy, strict, strictly, suit, sunset, supervisory, systematic, territory, terrorist, threaten, tiered, timeline, titled, toxicity, trend, turnover, UCPA, UK, unapproved, undertaken, undisclosed, unemployment, unpaid, unresponsive, unrest, Utah, viable, Virginia, whichever, yield

Removed: abatacept, Ablynx, acid, adjust, AG, agonism, Agonist, alfa, allocating, amending, Amgen, amino, antagonism, anti, Anticalin, arrangement, arranging, Asahi, assessment, ASU, atacicept, AtoxBio, Aurigene, Azymetric, BCMA, belatacept, belimumab, bifunctional, bind, binding, bintrafusp, BioNTech, Biopharma, bispecific, BiTE, blood, Bristol, building, camelidae, cellular, Chinook, clarifying, comparison, composed, consisting, Construct, costimulation, costimulatory, CStone, cybersecurity, DART, decelerate, deliverable, earn, Elpiscience, EMD, entirety, extinguishment, extracellular, facilitate, FASB, Fc, fragment, freeze, fused, Genmab, GSK, Harpoon, heavy, Ianalumab, Immunomodulation, improved, Incyte, inhibition, Inhibrx, interacting, Jaffray, Kahr, Kasei, leaving, left, library, link, memorandum, misappropriated, molecule, Multifunctional, Nanobody, network, Numab, NV, officially, Optimized, OSE, overcome, partner, peptide, Pharma, Piper, plasma, practice, principally, promised, rapid, Redirected, referendum, Regeneron, reltecimod, RemeGen, removing, rozibafusp, SA, Sanofi, satisfying, SE, Serono, Shattuck, Simplifying, simultaneously, slowdown, Squibb, stability, substantive, TACI, telitacicept, TGF, TheraMAB, TNF, Topic, transforming, transitional, Trap, Trident, trispecific, TriTAC, VEGF, VelociSuite, Vera, VISTA, Visterra, Xencor, XmAb

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

ALPN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

Exhibit 32.2

ALPINE IMMUNE SCIENCES, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Alpine Immune Sciences, Inc. (the “Company”) on Form 10-Q for the quarter ended March 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Paul Rickey, Senior Vice President and Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer) of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to my knowledge:

(1)The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.


/s/ Paul Rickey
Paul Rickey
Senior Vice President and Chief Financial Officer (Principal Accounting Officer and Principal Financial Officer)

May 12, 2022

A signed original of this written statement required by Section 906 of the Sarbanes-Oxley Act of 2002 has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request.

This certification accompanies the Report to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Alpine Immune Sciences, Inc. under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended (whether made before or after the date of the Report), irrespective of any general incorporation language contained in such filing.